Dr. Aleksander Słusarczyk presented the clinical case of a 75-year-old woman who presented with a two-month history of hematuria. Her medical history was notable for diabetes, prior myocardial ...

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Price transparency compliance is often “in-form” rather than “in-spirit,” with many machine-readable files failing to provide complete, accurate, and usable drug pricing data. Reform priorities ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...

HealthDay News — For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, ...

Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.